四川生理科学杂志2024，Vol.46Issue(3) ：600.DOI:10.1016/S0140-6736(24)00317-9

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed,high-risk,locally advanced cervical cancer(ENGOT-cx11/GOG-3047/KEYNOTE-A18):a randomised,double-blind,phase 3 clinical trial

Domenica Lorusso
四川生理科学杂志2024，Vol.46Issue(3) ：600.DOI:10.1016/S0140-6736(24)00317-9
✕
  • NETL
  • NSTL
  • 万方数据

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed,high-risk,locally advanced cervical cancer(ENGOT-cx11/GOG-3047/KEYNOTE-A18):a randomised,double-blind,phase 3 clinical trial

Domenica Lorusso
扫码查看

引用本文复制引用

出版年

2024
四川生理科学杂志
四川省生理科学会

四川生理科学杂志

影响因子：0.575
ISSN：1671-3885
段落导航相关论文